Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03
Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial.
In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data from the prespecified overall survival analysis of the DESTINY-Breast03 trial. The primary objective of the trial was to compare the anti-tumor activity as well as the safety and efficacy of T-DXd versus trastuzumab emtansine (T-DM1) in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.
The abstract entitled ‘Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03’ was presented at San Antonio Breast Cancer Symposium (SABCS), 06–10, December, 2022.
Questions:
- What is trastuzumab deruxtecan and what are its potential advantages over trastuzumab emtansine in patients with HER2+ unresectable/metastatic breast cancer? (0:15)
- Could you give us a brief overview of the DESTINY-Breast03 study and its interim efficacy and safety data? (2:08)
- What have been the findings of the overall survival analysis and the updated efficacy and safety analysis? (3:49)
- How clinically meaningful are these findings? (5:29)
- What will be the next steps in the clinical development of trastuzumab deruxtecan? (6:20)
Disclosures: Sara Hurvitz discloses grant/research support from Ambrx, Amgen, Arvinas, Astra Zeneca, Bayer, Cytomx, Daiichi-Sankyo, Dantari, Dignitana, Genentech/Roche, G1-Therapeutics, Gilead, GSK, Immunomedics, Eli Lilly, Macrogenics, Novartis, OBI Pharma, Orinove, Pfizer, Phoenix Molecular Designs, Ltd., Pieris, PUMA, Radius, Samumed, Sanofi, Seattle Genetics/Seagen and Zymeworks.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen.
Filmed as a highlight of SABCS 2022
Access more content on Breast Cancer
